Lebrikizumab treatment in adults with asthma.

By J. Corren, R. Lemanske, N. Hanania, P. Korenblat, M. Parsey, J. Arron, Jeffrey M Harris, H. Scheerens, Lawren C. Wu, Zheng Su and 4 more. New England Journal of Medicine, 2011

1,441 citations recorded by the source corpus.

Subfields: Dermatology, Immunology, Physiology

View Paper: https://www.semanticscholar.org/paper/08051869466976604dff189a0a221066e5f60dc8

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

1. TA Wynn
2. Andrew N. J. McKenzie
3. M. Colonna
4. D. Sheppard
5. S. Friedman
6. Jeremy S. Duffield
7. J. D. Di Santo
8. G. Eberl

In Physiology

1. Jeremy S. Duffield
2. Sally E. Wenzel
3. TA Wynn
4. M. Colonna
5. D. Sheppard
6. Ian M. Adcock
7. S. Friedman
8. P. Barnes

Citations in the corpus

• Macrophages and therapeutic resistance in cancer (2015, neutral): “Multiple agents targetingTH2cytokines and their receptorshavegonebeyondphase II clinical trials, with demonstrated efficacy in autoimmune disorders and acceptable safety profiles (Beck et al., 2014; Corren et al., 2011; Danese et al., 2015).”
• INTERLEUKIN-4- AND INTERLEUKIN-13-MEDIATED ALTERNATIVELY ACTIVATED MACROPHAGES: ROLES IN HOMEOSTASIS AND DISEASE (2013, neutral): “These findings extend to human studies, in which treatment with an IL-13neutralizing antibody led to improved lung function in asthmatic adult populations, particularly in patients exhibiting a Th2-high phenotype marked by elevated blood eosinophils, serum IgE, and periostin (165).”
• Therapy for Fibrotic Diseases: Nearing the Starting Line (2013, background): “Recent positive clinical data with lebrikizumab (Genentech), an anti– IL-13 antibody, in asthma patients with elevated serum periostin suggest that biomarkers could be used to identify patients who respond to anti–IL-13 treatment in fibrotic diseases as well (201).”
• Eosinophils: changing perspectives in health and disease (2012, background): “as the cytotoxic IL5Rαspecific monoclonal antibody benralizumab, or indirectly, such as the IL13specific mono clonal antibody lebrikizumab, may further enhance therapeutic outcomes 96, 97 .”
• Innate Lymphoid Cells: a new paradigm in immunology (2015, background): “For example, Mepolizumab (antibody to IL-5) andLebrikizumab (antibody to IL-13) have shownencouraging results in clinical trials against asthma (126, 127).”